Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL.

Ladjevardi S, Berglund A, Varenhorst E, Bratt O, Widmark A, Sandblom G.

BJU Int. 2013 Mar;111(3):381-8. doi: 10.1111/j.1464-410X.2012.11320.x. Epub 2012 Jul 3.

PMID:
22758210
2.

Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0.

Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellström K, Fransson P, Widmark A, Lambe M, Adolfsson J, Varenhorst E, Johansson JE, Stattin P; NPCR and PCBaSe Sweden.

Int J Epidemiol. 2013 Aug;42(4):956-67. doi: 10.1093/ije/dys068. Epub 2012 May 4.

3.

Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.

Davidsson S, Fiorentino M, Andrén O, Fang F, Mucci LA, Varenhorst E, Fall K, Rider JR.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2280-7. doi: 10.1158/1055-9965.EPI-11-0373. Epub 2011 Sep 27.

4.

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.

Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, Klarskov P, Mogensen P, Rasmussen F, Varenhorst E; SPCG-5 STUDY GROUP.

Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31.

PMID:
21627403
5.

Randomised prostate cancer screening trial: 20 year follow-up.

Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P.

BMJ. 2011 Mar 31;342:d1539. doi: 10.1136/bmj.d1539.

6.

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA, Andrén O.

BMC Med Genomics. 2010 Mar 16;3:8. doi: 10.1186/1755-8794-3-8.

7.

Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.

Ladjevardi S, Sandblom G, Berglund A, Varenhorst E.

Eur Urol. 2010 Apr;57(4):631-8. doi: 10.1016/j.eururo.2009.03.007. Epub 2009 Mar 10.

PMID:
19299069
8.

PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.

Robinson D, Sandblom G, Johansson R, Garmo H, Aus G, Hedlund PO, Varenhorst E; Scandinavian Prostate Cancer Group.

Urology. 2008 Oct;72(4):903-7. doi: 10.1016/j.urology.2008.05.026. Epub 2008 Jul 17.

PMID:
18639324
9.

Reliability of death certificates in prostate cancer patients.

Fall K, Strömberg F, Rosell J, Andrèn O, Varenhorst E; South-East Region Prostate Cancer Group.

Scand J Urol Nephrol. 2008;42(4):352-7. doi: 10.1080/00365590802078583.

PMID:
18609293
10.

Prostate cancer screening.

Sandblom G, Varenhorst E.

Cancer Causes Control. 2008 Dec;19(10):1411. doi: 10.1007/s10552-008-9180-3. Epub 2008 Jun 3. No abstract available.

PMID:
18521712
11.

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA.

J Natl Cancer Inst. 2008 Jun 4;100(11):815-25. doi: 10.1093/jnci/djn150. Epub 2008 May 27.

12.

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J; SPCG-5 Study Group.

Scand J Urol Nephrol. 2008;42(3):220-9. doi: 10.1080/00365590801943274.

PMID:
18432528
13.
14.

Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase.

Robinson D, Sandblom G, Johansson R, Garmo H, Stattin P, Mommsen S, Varenhorst E; Scandinavian Prostate Cancer Group (SPCG)-5.

J Urol. 2008 Jan;179(1):117-22; discussion 122-3. Epub 2007 Nov 12.

PMID:
17997442
15.

Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.

Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, Bill-Axelson A, Bratt O, Damber JE, Hellström K, Hellström M, Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Törnblom M, Widmark A, Stattin P.

Scand J Urol Nephrol. 2007;41(6):456-77.

PMID:
17934985
16.

Long-term follow-up of conservatively managed incidental carcinoma of the prostate: a multivariate analysis of prognostic factors.

Robinson D, Aus G, Bak J, Gorecki T, Herder A, Rosell J, Varenhorst E.

Scand J Urol Nephrol. 2007;41(2):103-9.

PMID:
17454947
17.

Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk.

Andersson P, Varenhorst E, Söderkvist P.

Eur J Cancer. 2006 Nov;42(16):2833-7. Epub 2006 Sep 28.

PMID:
17010601
18.
19.

[Prostatic cancer in Sweden 1998-2003. Drastic change of the disease panorama].

Varenhorst E, Garmo H, Holmberg L, Stattin P, Johansson JE.

Lakartidningen. 2006 Feb 1-7;103(5):285-8. Swedish. No abstract available.

PMID:
16512566
20.

Diffusion and economic consequences of health technologies in prostate cancer care in Sweden, 1991-2002.

Sennfält K, Carlsson P, Varenhorst E.

Eur Urol. 2006 Jun;49(6):1028-34. Epub 2006 Jan 6.

PMID:
16417962
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk